Clinicopathologic characteristics of the 19 patients with HL
Patient no. . | Histology . | Age, y/sex . | Disease stage . | . | Therapy . | PR/relapse* . | . | Outcome† . | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NLPHL | 52/M | CS-IIA | RT | Rel.;n = 2 | Alive | |||
| 2 | NLPHL | 42/F | CS-IA | 4 | ABVD+ RT | No | Alive | ||
| 3 | NLPHL | 14/M | CS-IIB | 4COPP/ABV+RT;36Gy | Rel.;n = 1; | ABMT | Alive | ||
| 4 | NLPHL | 22/M | CS-IA | NA | No | NA | |||
| 5 | NLPHL‡ | 15/M | CS-IIA | NA | Rel.;n = 1 | Alive | |||
| 6 | NLPHL | 72/F | CS-IIIA | 8 | CVPP | No | Alive | ||
| 7 | NLPHL | 27/M | CS-IA | 4 | ABVD+ RT | No | Alive | ||
| 8 | NLPHL | 63/M | CS-IA | 4 | ABVD+ RT | No | Alive | ||
| 9 | NLPHL | 42/M | CS-IIA | RT | No | Alive | |||
| 10 | NLPHL | 11/M | CS-IA | NA | NA | NA | |||
| 11 | HL-NS | 22/F | CS-IIA | 6 | ABVD | No | Alive | ||
| 12 | HL-NS | 40/F | CS-IVA | 6 | ABVD | No | Alive | ||
| 13 | HL-NS | 17/F | CS-IIIB | 4 | ABVD | PR; IEV + ABMT | Alive | ||
| 14 | HL-NS | 33/F | CS-IVA | 8 | ABVD+ RT | No | Alive | ||
| 15 | HL-MC | 67/F | CS-IIIB | 6 | ABVD+ RT | No | Alive | ||
| 16 | HL-NS | 24/F | CS-IVB | 8 | BEACOPP+ RT | No | Alive | ||
| 17 | HL-MC | 28/M | CS-IA | RT | No | Alive | |||
| 18 | HL-MC | 35/M | CS-IIB | 6 | ABVD | No | Alive | ||
| 19 | HL-NS | 67/M | CS-IA | 4 | ABVD+ RT | No | Alive | ||
Patient no. . | Histology . | Age, y/sex . | Disease stage . | . | Therapy . | PR/relapse* . | . | Outcome† . | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NLPHL | 52/M | CS-IIA | RT | Rel.;n = 2 | Alive | |||
| 2 | NLPHL | 42/F | CS-IA | 4 | ABVD+ RT | No | Alive | ||
| 3 | NLPHL | 14/M | CS-IIB | 4COPP/ABV+RT;36Gy | Rel.;n = 1; | ABMT | Alive | ||
| 4 | NLPHL | 22/M | CS-IA | NA | No | NA | |||
| 5 | NLPHL‡ | 15/M | CS-IIA | NA | Rel.;n = 1 | Alive | |||
| 6 | NLPHL | 72/F | CS-IIIA | 8 | CVPP | No | Alive | ||
| 7 | NLPHL | 27/M | CS-IA | 4 | ABVD+ RT | No | Alive | ||
| 8 | NLPHL | 63/M | CS-IA | 4 | ABVD+ RT | No | Alive | ||
| 9 | NLPHL | 42/M | CS-IIA | RT | No | Alive | |||
| 10 | NLPHL | 11/M | CS-IA | NA | NA | NA | |||
| 11 | HL-NS | 22/F | CS-IIA | 6 | ABVD | No | Alive | ||
| 12 | HL-NS | 40/F | CS-IVA | 6 | ABVD | No | Alive | ||
| 13 | HL-NS | 17/F | CS-IIIB | 4 | ABVD | PR; IEV + ABMT | Alive | ||
| 14 | HL-NS | 33/F | CS-IVA | 8 | ABVD+ RT | No | Alive | ||
| 15 | HL-MC | 67/F | CS-IIIB | 6 | ABVD+ RT | No | Alive | ||
| 16 | HL-NS | 24/F | CS-IVB | 8 | BEACOPP+ RT | No | Alive | ||
| 17 | HL-MC | 28/M | CS-IA | RT | No | Alive | |||
| 18 | HL-MC | 35/M | CS-IIB | 6 | ABVD | No | Alive | ||
| 19 | HL-NS | 67/M | CS-IA | 4 | ABVD+ RT | No | Alive | ||
RT indicates radiation therapy; ABVD, Adriamycin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide, Oncovin, procarbazine, prednisone; ABV, Adriamycin, bleomycin, vinblastine; CVPP, cyclophosphamide, vincristine, prednisone, procarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; PR, partial remission; CR, complete remission; Rel., relapse; NA, not available; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; HL-NS, Hodgkin lymphoma nodular sclerosis; HL-MC, Hodgkin lymphoma, mixed cellularity.
If relapse occurred, number of instances and subsequent treatment are also listed. If PR occurred, treatment is also listed.
All indications of “Alive” entailed CR.
Nodular and diffuse.